Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 5/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.65 |
| ▸ | ACHE | P22303 | 2/20 | 0.59 |
| ▸ | FLT3 | P36888 | 2/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.54 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.54 |
| ▸ | RELA | Q04206 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.50 |
| ▸ | AXL | P30530 | 1/20 | 0.50 |
| ▸ | NCF1 | P14598 | 1/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | CA7 | P43166 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL806296 | 0.95 | CYP2A6 (0.64) | CYP2A6CYP1A2ACHEFLT3TDP1 | |
| SCHEMBL12357268 | 0.95 | CYP2A6 (0.59) | CYP2A6CYP1A2ACHEFLT3TDP1 | |
| SCHEMBL15869806 | 0.91 | CYP2A6 (0.54) | CYP2A6CYP1A2ACHEFLT3TDP1 | |
| SCHEMBL12031848 | 0.91 | HSD17B1 (0.68) | CYP2A6CYP1A2ACHEFLT3HSD17B1 | |
| SCHEMBL26710972 | 0.89 | CYP2A6 (0.52) | CYP2A6CYP1A2ACHEFLT3TDP1 | |
| SCHEMBL29447161 | 0.87 | CYP1A2 (0.79) | CYP2A6CYP1A2HSD17B1HSD17B2KDM4E | |
| SCHEMBL443070 | 0.87 | CYP1A2 (0.79) | CYP2A6CYP1A2HSD17B1HSD17B2KDM4E | |
| Hydrochloric Acid SCHEMBL9590959 | 0.86 | CYP2A6 (0.58) | CYP2A6CYP1A2ACHEFLT3HSD17B1 | |
| SCHEMBL10299553 | 0.84 | ACHE (0.58) | CYP2A6CYP1A2ACHETDP1HSD17B1 | |
| SCHEMBL12337061 | 0.82 | HSD17B1 (0.68) | CYP2A6CYP1A2ACHEHSD17B1HSD17B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 657 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2003075913-A1 | TOPICAL COMPOSTIONS COMPRISING FURFURYL DERIVATIVES AND THEIR USE FOR THE TREATMENT OF DERMATOLOGIC DISORDERS | GHISALBERTI CARLO (BR) | 2003-09-18 | — | — | WO | claimed |
| EP-0322068-B1 | DERIVATIVES OF THIAZOLIDINE-4-CARBOXYLIC ACID HAVING PHARMACOLOGICAL ACTIVITY | ZAMBON GROUP S.p.A. (IT) | 1993-07-28 | — | — | EP | claimed |
| EP-0254354-B1 | PHARMACEUTICALLY USEFUL DERIVATIVES OF THIAZOLIDINE-4-CARBOXYLIC ACID | ZAMBON S.p.A. (IT) | 1993-03-31 | — | — | EP | claimed |
| US-5068458-A | Chemical process for halogenating 2-methyl-6-methoxynaphthalene | BEECHAM GROUP P.L.C. (GB) | 1991-11-26 | — | — | US | claimed |
| EP-0415524-A1 | Process for the production of 2-halomethyl-6-methoxy naphthalene | Beecham Group p.l.c. (GB) | 1991-03-06 | — | — | EP | claimed |
| US-4952596-A | Derivatives of thiazolidine-4-carboxylic acid having pharmacological activity | ZAMBON S.P.A. (IT) | 1990-08-28 | — | — | US | claimed |
| US-4354974-A | Clavudienes | BEECHAM GROUP LIMITED (GB) | 1982-10-19 | — | — | US | claimed |
| JP-3038540-A | — | — | None | — | — | JP | disclosed |
| US-20240024266-A1 | Therapeutic Agent or Prophylactic Agent for COVID-19 | HIROSHIMA UNIVERSITY (JP) | 2024-01-25 | — | — | US | disclosed |
| US-11858907-B2 | Kinase modulators | RHIZEN PHARMACEUTICALS AG (CH) | 2024-01-02 | — | — | US | disclosed |
| US-11858907-B2 | Kinase modulators | RHIZEN PHARMACEUTICALS AG (CH) | 2024-01-02 | — | — | US | disclosed |
| WO-2023214325-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES AND USES THEREOF AS TET2 INHIBITORS | NOVARTIS AG (CH) | 2023-11-09 | — | — | WO | disclosed |
| WO-2023142996-A1 | METHOD FOR PREVENTING OR TREATING DISEASE OR DISORDER ASSOCIATED WITH ANTINEOPLASTIC AGENT | 上海岸阔医药科技有限公司 | 2023-08-03 | — | — | WO | disclosed |
| EP-0415524-A1 | Process for the production of 2-halomethyl-6-methoxy naphthalene | Beecham Group p.l.c. (GB) | 1991-03-06 | — | — | EP | disclosed |
| EP-0415524-A1 | Process for the production of 2-halomethyl-6-methoxy naphthalene | Beecham Group p.l.c. (GB) | 1991-03-06 | — | — | EP | disclosed |
| JP-H0338540-A | CHEMICAL PROCESS | BEECHAM GROUP PLC | 1991-02-19 | — | — | JP | disclosed |
| US-4952596-A | Derivatives of thiazolidine-4-carboxylic acid having pharmacological activity | ZAMBON S.P.A. (IT) | 1990-08-28 | — | — | US | disclosed |
| US-4276305-A | INSECTICIDES, MITICIDES | HOFFMANN-LA ROCHE INC. (US) | 1981-06-30 | — | — | US | disclosed |
| US-4140764-A | ISOCLAVULANIC ACID OR SALT, OXAPENICILLINS IN COMBINATION WITH PENCILLINS OR CEPHALOSPORINS | BEECHAM GROUP LIMITED (GB) | 1979-02-20 | — | — | US | disclosed |
| US-4123540-A | Isoclavulanic acid as an antibacterial and a β-lactamase inhibitor | BEECHAM GROUP LIMITED (GB) | 1978-10-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11858907-B2 | Kinase modulators | RPS6KA1, RPS6KA2, PRKAR2A | CYP2A6 3540/4885CYP1A2 2024/4885ACHE 3993/4885 |
| US-20240024266-A1 | Therapeutic Agent or Prophylactic Agent for COVID-19 | PIN1, ACE2, ACE | CYP2A6 3671/4885CYP1A2 4049/4885ACHE 1618/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.